Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis
文摘
NNT can provide an additional measure of comparative efficacy of DMTs across trials [85/85]. NNTs were similar across key clinical outcomes for teriflunomide, DMF &$2 fingolimod [84/85]. Teriflunomide had a lower NNT to prevent some severe relapses vs DMF or fingolimod [84/85]. Only teriflunomide showed consistently low NNTs to prevent disability progression [83/85]. These NNT data have clinical relevance and may help to inform treatment decisions [83/85].